Sagimet Biosciences Inc (NASDAQ:SGMT)’s traded shares stood at 0.66 million during the last session, with the company’s beta value hitting 2.56. At the close of trading, the stock’s price was $4.39, to imply an increase of 2.81% or $0.12 in intraday trading. The SGMT share’s 52-week high remains $20.71, putting it -371.75% down since that peak but still an impressive 45.56% since price per share fell to its 52-week low of $2.39. The company has a valuation of $134.66M, with an average of 2.01 million shares in intraday trading volume over the past 10 days and average of 907.22K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Sagimet Biosciences Inc (SGMT), translating to a mean rating of 1.25. Of 5 analyst(s) looking at the stock, 0 analyst(s) give SGMT a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.63.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
After registering a 2.81% upside in the last session, Sagimet Biosciences Inc (SGMT) has traded red over the past five days. The 5-day price performance for the stock is -15.25%, and -23.39% over 30 days. With these gigs, the year-to-date price performance is -2.44%. Short interest in Sagimet Biosciences Inc (NASDAQ:SGMT) saw shorts transact 4.17 million shares and set a 1.37 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, SGMT has been trading -36.67% off suggested target high and -36.67% from its likely low.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
Looking at statistics comparing Sagimet Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. Sagimet Biosciences Inc (SGMT) shares are 36.34% up over the last 6 months, with its year-to-date growth rate higher than industry average at 39.47% against 16.60%. The rating firms project that company’s revenue will shrink -100.00% compared to the previous financial year.
SGMT Dividends
Sagimet Biosciences Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Sagimet Biosciences Inc insiders hold 14.11% of total outstanding shares, with institutional holders owning 66.94% of the shares at 77.94% float percentage. In total, 66.94% institutions holds shares in the company.
We also have Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust as the top two Mutual Funds with the largest holdings of the Sagimet Biosciences Inc (SGMT) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 763.99 shares. This is just over 2.49% of the total shares, with a market valuation of $3.35 million. Data from the same date shows that the other fund manager holds a little less at 408.12, or 1.33% of the shares, all valued at about 1.79 million.
